AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39448200 — intervention group
Group type: COMPARATOR
Intervention: Non-profiled squamous cell carcinomas (non-AGAs+NP SCC, n=20)
Number of subjects: 44
Study 39448207 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 60
Study 39448216 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIME programme (digital health-supported lifestyle intervention)
Number of subjects: 16
Study 39448216 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 16
Study 39448218 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg micronised progesterone (mP) per day in continuous combination with 1 mg oestradiol
Number of subjects: 520
Study 39448218 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg norethisterone acetate (NETA) per day in continuous combination with 1 mg oestradiol
Number of subjects: 520
Study 39448218 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg micronised progesterone (mP) with 1 mg oestradiol
Number of subjects: 520
Study 39448217 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen
Number of subjects: 1110
Study 39448217 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen
Number of subjects: 1110
Study 39448317 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-μFR
Number of subjects: 242
Study 39448323 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger puppet (n = 40)
Number of subjects: 160
Study 39448323 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinwheel (n = 40)
Number of subjects: 160
Study 39448323 — intervention group
Group type: EXPERIMENTAL
Intervention: Abeslang puzzle (n = 40)
Number of subjects: 160
Study 39448323 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 40)
Number of subjects: 160
Study 39448350 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab first-line maintenance treatment
Number of subjects: 595
Study 39448350 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab first-line maintenance treatment followed by second-line enfortumab vedotin
Number of subjects: 595
Study 39448350 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab first-line maintenance treatment followed by platinum-based chemotherapy (PBC)
Number of subjects: 595
Study 39448427 — intervention group
Group type: EXPERIMENTAL
Intervention: VMI ASPECTS
Number of subjects: 84
Study 39448427 — intervention group
Group type: EXPERIMENTAL
Intervention: Total iodine content
Number of subjects: 84
Study 39448427 — intervention group
Group type: EXPERIMENTAL
Intervention: VMI infarct volume
Number of subjects: 84
Study 39448427 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined predictors (VMI ASPECTS, total iodine content, VMI infarct volume)
Number of subjects: 84
Study 39448701 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with delayed cerebral ischemia (DCI)
Number of subjects: 587
Study 39448701 — intervention group
Group type: COMPARATOR
Intervention: Patients without delayed cerebral ischemia (DCI)
Number of subjects: 587
Study 39448701 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with modified Fisher score less than 3
Number of subjects: 587
Study 39448701 — intervention group
Group type: COMPARATOR
Intervention: Patients with modified Fisher score greater than or equal to 3
Number of subjects: 587
Study 39448724 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Frequency Vibration (V)
Number of subjects: 144
Study 39448724 — intervention group
Group type: COMPARATOR
Intervention: Cotton Roll (CR)
Number of subjects: 144
Study 39448724 — intervention group
Group type: COMPARATOR
Intervention: Elastomeric Wafer (EW)
Number of subjects: 144
Study 39448724 — intervention group
Group type: COMPARATOR
Intervention: Open Mouth (OM)
Number of subjects: 144
Study 39448816 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic hydrocortisone (HC)
Number of subjects: 404
Study 39448816 — intervention group
Group type: EXPERIMENTAL
Intervention: BPD assessment at 40 weeks of postmenstrual age
Number of subjects: 404
Study 39448906 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic papillectomy with stent placement
Number of subjects: 79
Study 39448906 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic papillectomy without stent placement
Number of subjects: 79
Study 39448906 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting group (common bile duct stent placement)
Number of subjects: 79
Study 39448906 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting group (pancreatic duct stent placement)
Number of subjects: 79
Study 39448911 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 205
Study 39448911 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab and olaparib/PARPi
Number of subjects: 205
Study 39448938 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention in primary care following robot-assisted radical cystectomy
Number of subjects: 20
Study 39448966 — intervention group
Group type: EXPERIMENTAL
Intervention: Spartalizumab (300 mg every 3 weeks) with platinum-doublet chemotherapy (PDC)
Number of subjects: 0
Study 39448966 — intervention group
Group type: EXPERIMENTAL
Intervention: Spartalizumab with PDC and canakinumab
Number of subjects: 0
Study 39448986 — intervention group
Group type: EXPERIMENTAL
Intervention: tixagevimab/cilgavimab (300 mg)
Number of subjects: 229
Study 39448991 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene fiber reinforced bulk fill resin composite restorations
Number of subjects: 240
Study 39448991 — intervention group
Group type: COMPARATOR
Intervention: Bulk fill resin composite restorations
Number of subjects: 240
Study 39448999 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-monthly PrEP dispensing with interim HIV self-testing (HIVST)
Number of subjects: 55
Study 39448999 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care three-monthly PrEP dispensing with clinic-based HIV testing
Number of subjects: 55
Study 39449056 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional exercise program (45-minute sessions, twice per week for 14 weeks)
Number of subjects: 82
Study 39449056 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional exercise program
Number of subjects: 82
Study 39449056 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercise group (flexibility exercises, same duration and frequency)
Number of subjects: 82
Study 39449089 — intervention group
Group type: EXPERIMENTAL
Intervention: After-school program voucher only
Number of subjects: 480
Study 39449089 — intervention group
Group type: EXPERIMENTAL
Intervention: Summer day camp voucher only
Number of subjects: 480
Study 39449089 — intervention group
Group type: EXPERIMENTAL
Intervention: After-school and summer day camp vouchers
Number of subjects: 480
Study 39449089 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 480
Study 39449120 — intervention group
Group type: EXPERIMENTAL
Intervention: 2021 CKD-EPI equation
Number of subjects: 15773
Study 39449120 — intervention group
Group type: COMPARATOR
Intervention: 2009 CKD-EPI equation
Number of subjects: 15773
Study 39449387 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of Female Body Scale-KFB
Number of subjects: 301
Study 39449387 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Health Literacy Screening Tool-BRIEF
Number of subjects: 301
Study 39449962 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplant Wellness Program (TWP) - 12-week exercise intervention with individualized and group behavior change support
Number of subjects: 0
Study 39449962 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplant Wellness Program (TWP) - 12-week exercise intervention
Number of subjects: 0
Study 39449962 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplant Wellness Program (TWP)
Number of subjects: 0
Study 39449979 — intervention group
Group type: EXPERIMENTAL
Intervention: Leighton-Rex scale
Number of subjects: 24
Study 39449979 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-CLEAR scale
Number of subjects: 24
Study 39450267 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-day modified fasting (ADMF)
Number of subjects: 20
Study 39450267 — intervention group
Group type: COMPARATOR
Intervention: Continuous low-calorie diet (LCD)
Number of subjects: 20
Study 39450294 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-derived fractional flow reserve (CT-FFR)
Number of subjects: 108
Study 39450294 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated module for CT-FFR evaluations
Number of subjects: 108
Study 39450437 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year multidomain lifestyle intervention including dietary advice, exercise, cognitive training, and vascular risk management
Number of subjects: 568
Study 39450437 — intervention group
Group type: COMPARATOR
Intervention: Regular health advice control group
Number of subjects: 568
Study 39450683 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapokibart 300 mg every 2 weeks
Number of subjects: 476
Study 39450683 — intervention group
Group type: COMPARATOR
Intervention: Switching from placebo to stapokibart 300 mg every 2 weeks
Number of subjects: 476
Study 39450717 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT analysis
Number of subjects: 297
Study 39450717 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent underexpansion
Number of subjects: 297
Study 39450717 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year incidence of target vessel failure
Number of subjects: 297
Study 39450752 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular inflammation without evidence of an antibody-mediated response
Number of subjects: 6798
Study 39450752 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody-mediated rejection
Number of subjects: 6798
Study 39450752 — intervention group
Group type: EXPERIMENTAL
Intervention: Probable antibody-mediated rejection
Number of subjects: 6798
Study 39450752 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly recognized microvascular inflammation phenotypes
Number of subjects: 6798
Study 39450762 — intervention group
Group type: EXPERIMENTAL
Intervention: Darolutamide 600 mg twice daily
Number of subjects: 30
Study 39450759 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs
Number of subjects: 135
Study 39450759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 39450934 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (6 weekly individual sessions)
Number of subjects: 92
Study 39450934 — intervention group
Group type: COMPARATOR
Intervention: Social attention control (6 weekly sessions)
Number of subjects: 92
Study 39451095 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib plus enzalutamide
Number of subjects: 599
Study 39451095 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus enzalutamide
Number of subjects: 599
Study 39451783 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate Cancer Patient Empowerment Program (PC-PEP)
Number of subjects: 0
Study 39451783 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39452487 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitors
Number of subjects: 158
Study 39452487 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 158
Study 39452792 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenursing
Number of subjects: 0
Study 39452792 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39452892 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 0
Study 39452892 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg
Number of subjects: 0
Study 39452892 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39452894 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib plus nivolumab
Number of subjects: 0
Study 39452894 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39452950 — intervention group
Group type: EXPERIMENTAL
Intervention: D-RVd followed by D-R maintenance
Number of subjects: 0
Study 39452950 — intervention group
Group type: COMPARATOR
Intervention: RVd followed by R maintenance
Number of subjects: 0
Study 39453348 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education about the operative process and pain management
Number of subjects: 52
Study 39453348 — intervention group
Group type: COMPARATOR
Intervention: Control group (no patient education)
Number of subjects: 52
Study 39453356 — intervention group
Group type: EXPERIMENTAL
Intervention: Survodutide, a dual glucagon and GLP-1 receptor agonist, administered subcutaneously once weekly
Number of subjects: 0
Study 39453356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39453357 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study 39453357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39453394 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervex-Brush
Number of subjects: 160
Study 39453394 — intervention group
Group type: COMPARATOR
Intervention: Orcellex
Number of subjects: 160
Study 39453395 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple hysterectomy
Number of subjects: 800
Study 39453395 — intervention group
Group type: COMPARATOR
Intervention: Radical hysterectomy
Number of subjects: 800
Study 39453400 — intervention group
Group type: EXPERIMENTAL
Intervention: PLLA-SCA (8 mL of sterile water + 1 mL of 2% lidocaine)
Number of subjects: 67
Study 39453400 — intervention group
Group type: EXPERIMENTAL
Intervention: PLLA-SCA
Number of subjects: 67
Study 39453400 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 67
Study 39453454 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh technique
Number of subjects: 239
Study 39453454 — intervention group
Group type: COMPARATOR
Intervention: RTL technique
Number of subjects: 239
Study 39453550 — intervention group
Group type: EXPERIMENTAL
Intervention: glo HTPs (Standard Mode)
Number of subjects: 75
Study 39453550 — intervention group
Group type: EXPERIMENTAL
Intervention: glo HTPs (Boost Mode)
Number of subjects: 75
Study 39453550 — intervention group
Group type: COMPARATOR
Intervention: Usual Brand (UB) cigarettes
Number of subjects: 75
Study 39453550 — intervention group
Group type: COMPARATOR
Intervention: Nicotine gum
Number of subjects: 75
Study 39453705 — intervention group
Group type: EXPERIMENTAL
Intervention: PSP Wellbeing Course (Internet-delivered cognitive behavioral therapy)
Number of subjects: 41
Study 39453735 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 0
Study 39453735 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 0
Study 39453735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39453735 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 0
Study 39453738 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ferric derisomaltose (FDI)
Number of subjects: 0
Study 39453738 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 39453772 — intervention group
Group type: EXPERIMENTAL
Intervention: Iptacopan (200 mg) twice daily for 24 months
Number of subjects: 443
Study 39453772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study 39453837 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg once daily)
Number of subjects: 6609
Study 39453837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6609
Study 39453840 — intervention group
Group type: COMPARATOR
Intervention: Interpectoral-pectoserratus block (single block)
Number of subjects: 116
Study 39453840 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpectoral-pectoserratus combined with deep parasternal intercostal block (combined block)
Number of subjects: 116
Study 39453840 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined block
Number of subjects: 116
Study 39453840 — intervention group
Group type: COMPARATOR
Intervention: Single block and combined block
Number of subjects: 116
Study 39453950 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood Early Oral Aging Syndrome (CEOAS) index for the primary dentition
Number of subjects: 0
Study 39454044 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison micro-interventions (days 4-5)
Number of subjects: 30
Study 39454044 — intervention group
Group type: EXPERIMENTAL
Intervention: Support micro-interventions (days 6-7)
Number of subjects: 30
Study 39454044 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall micro-intervention approach
Number of subjects: 30
Study 39454050 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney action team recommendations through electronic health record
Number of subjects: 4003
Study 39454050 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4003
Study 39454076 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Coaching (HC)
Number of subjects: 200
Study 39454076 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study 39454079 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower perceived social support (PSS)
Number of subjects: 178
Study 39454196 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak Expiratory Flow (PEF) feedback
Number of subjects: 354
Study 39454196 — intervention group
Group type: COMPARATOR
Intervention: Supportive counseling
Number of subjects: 354
Study 39454227 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg once daily
Number of subjects: 16
Study 39454281 — intervention group
Group type: EXPERIMENTAL
Intervention: IM cohort 1c (25/25/50 mg/m2 MWF)
Number of subjects: 229
Study 39454281 — intervention group
Group type: EXPERIMENTAL
Intervention: IV cohort (25/25/50 mg/m2 MWF)
Number of subjects: 229
Study 39454281 — intervention group
Group type: EXPERIMENTAL
Intervention: IM cohort
Number of subjects: 229
Study 39454281 — intervention group
Group type: EXPERIMENTAL
Intervention: IV cohort
Number of subjects: 229
Study 39454458 — intervention group
Group type: EXPERIMENTAL
Intervention: FLEX-D (64% plant protein)
Number of subjects: 19
Study 39454458 — intervention group
Group type: COMPARATOR
Intervention: CON-D (36% plant protein)
Number of subjects: 19
Study 39454617 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximod (doses not specified)
Number of subjects: 34
Study 39454668 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized, high-fidelity implementation of the Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F)
Number of subjects: 225
Study 39454668 — intervention group
Group type: COMPARATOR
Intervention: Usual care condition
Number of subjects: 225
Study 39454668 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized, high-fidelity implementation of the M-CHAT-R/F
Number of subjects: 225
Study 39454735 — intervention group
Group type: EXPERIMENTAL
Intervention: Cam+MDT
Number of subjects: 39
Study 39454735 — intervention group
Group type: COMPARATOR
Intervention: Cam
Number of subjects: 39
Study 39454735 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 39
Study 39454756 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted mass-spectrometry-based proteomics
Number of subjects: 57
Study 39454756 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR
Number of subjects: 57
Study 39454756 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture
Number of subjects: 57
Study 39454756 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteomics, PCR, and culture combined
Number of subjects: 57
Study 39454756 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteomics
Number of subjects: 57
Study 39454939 — intervention group
Group type: EXPERIMENTAL
Intervention: FIL-EAS-ic pathway (hospital-at-home care pathway)
Number of subjects: 454
Study 39454939 — intervention group
Group type: COMPARATOR
Intervention: Conventional hospitalization pathway
Number of subjects: 454
Study 39454963 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive Interpersonal Therapy (MIT)
Number of subjects: 47
Study 39454963 — intervention group
Group type: COMPARATOR
Intervention: Structured clinical management (control)
Number of subjects: 47
Study 39454998 — intervention group
Group type: EXPERIMENTAL
Intervention: Oronasal CPAP
Number of subjects: 20
Study 39454998 — intervention group
Group type: COMPARATOR
Intervention: Oral CPAP
Number of subjects: 20
Study 39454998 — intervention group
Group type: COMPARATOR
Intervention: Nasal CPAP
Number of subjects: 20
Study 39454998 — intervention group
Group type: EXPERIMENTAL
Intervention: Oronasal CPAP in lateral position
Number of subjects: 20
Study 39455065 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg (de novo)
Number of subjects: 0
Study 39455065 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg (de novo)
Number of subjects: 0
Study 39455065 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg (continued)
Number of subjects: 0
Study 39455065 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg (continued)
Number of subjects: 0
Study 39455063 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 0
Study 39455063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39455493 — intervention group
Group type: EXPERIMENTAL
Intervention: ZXR00V/ZXW150 (VLF group)
Number of subjects: 60
Study 39455493 — intervention group
Group type: COMPARATOR
Intervention: ZXR00/ZXT150 (UVF group)
Number of subjects: 60
Study 39455495 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofol
Number of subjects: 174
Study 39455495 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 174
Study 39455572 — intervention group
Group type: EXPERIMENTAL
Intervention: Later Eaters (LE)
Number of subjects: 26
Study 39455572 — intervention group
Group type: COMPARATOR
Intervention: Early Eaters (EE)
Number of subjects: 26
Study 39455575 — intervention group
Group type: EXPERIMENTAL
Intervention: rezpegaldesleukin (REZPEG) 24 µg/kg
Number of subjects: 0
Study 39455575 — intervention group
Group type: EXPERIMENTAL
Intervention: rezpegaldesleukin (REZPEG) 10 to 12 µg/kg
Number of subjects: 0
Study 39455729 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 0
Study 39455729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0